Cargando…

Unmasking Differential Effects of Rosiglitazone and Pioglitazone in the Combination Treatment with n-3 Fatty Acids in Mice Fed a High-Fat Diet

Combining pharmacological treatments and life style interventions is necessary for effective therapy of major diseases associated with obesity, which are clustered in the metabolic syndrome. Acting via multiple mechanisms, combination treatments may reduce dose requirements and, therefore, lower the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kus, Vladimir, Flachs, Pavel, Kuda, Ondrej, Bardova, Kristina, Janovska, Petra, Svobodova, Michaela, Jilkova, Zuzana Macek, Rossmeisl, Martin, Wang-Sattler, Rui, Yu, Zhonghao, Illig, Thomas, Kopecky, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3207833/ https://www.ncbi.nlm.nih.gov/pubmed/22073272 http://dx.doi.org/10.1371/journal.pone.0027126

Ejemplares similares

Preservation of Metabolic Flexibility in Skeletal Muscle by a Combined Use of n-3 PUFA and Rosiglitazone in Dietary Obese Mice
por: Horakova, Olga, et al.
Publicado: (2012)

Reduced Number of Adipose Lineage and Endothelial Cells in Epididymal fat in Response to Omega-3 PUFA in Mice Fed High-Fat Diet
por: Adamcova, Katerina, et al.
Publicado: (2018)

Additive Effects of Omega-3 Fatty Acids and Thiazolidinediones in Mice Fed a High-Fat Diet: Triacylglycerol/Fatty Acid Cycling in Adipose Tissue
por: Bardova, Kristina, et al.
Publicado: (2020)

AMP-activated Protein Kinase α2 Subunit Is Required for the Preservation of Hepatic Insulin Sensitivity by n-3 Polyunsaturated Fatty Acids
por: Jelenik, Tomas, et al.
Publicado: (2010)

The inhibition of fat cell proliferation by n-3 fatty acids in dietary obese mice
por: Hensler, Michal, et al.
Publicado: (2011)

Combined intervention with pioglitazone and n-3 fatty acids in metformin-treated type 2 diabetic patients: improvement of lipid metabolism
por: Veleba, Jiri, et al.
Publicado: (2015)

Adipose tissue-specific ablation of PGC-1β impairs thermogenesis in brown fat
por: Funda, Jiří, et al.
Publicado: (2022)

Plasma Acylcarnitines and Amino Acid Levels As an Early Complex Biomarker of Propensity to High-Fat Diet-Induced Obesity in Mice
por: Horakova, Olga, et al.
Publicado: (2016)

Metformin acutely lowers blood glucose levels by inhibition of intestinal glucose transport
por: Horakova, Olga, et al.
Publicado: (2019)

Thermoneutral housing promotes hepatic steatosis in standard diet-fed C57BL/6N mice, with a less pronounced effect on NAFLD progression upon high-fat feeding
por: Horakova, Olga, et al.
Publicado: (2023)

Metabolic Effects of n-3 PUFA as Phospholipids Are Superior to Triglycerides in Mice Fed a High-Fat Diet: Possible Role of Endocannabinoids
por: Rossmeisl, Martin, et al.
Publicado: (2012)

Rosiglitazone and Pioglitazone Alter Aromatase Kinetic Properties in Human Granulosa Cells
por: Araki, Takako, et al.
Publicado: (2011)

Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings
por: Niyomnaitham, Suvimol, et al.
Publicado: (2014)

Induction of lipid oxidation by polyunsaturated fatty acids of marine origin in small intestine of mice fed a high-fat diet
por: van Schothorst, Evert M, et al.
Publicado: (2009)

Dysregulation of epicardial adipose tissue in cachexia due to heart failure: the role of natriuretic peptides and cardiolipin
por: Janovska, Petra, et al.
Publicado: (2020)

A pyrexic effect of FGF21 independent of energy expenditure and UCP1
por: Zouhar, Petr, et al.
Publicado: (2021)

Krill Oil Supplementation Reduces Exacerbated Hepatic Steatosis Induced by Thermoneutral Housing in Mice with Diet-Induced Obesity
por: Sistilli, Gabriella, et al.
Publicado: (2021)

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study
por: Juurlink, David N, et al.
Publicado: (2009)

Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies
por: Deeg, Mark A., et al.
Publicado: (2008)

Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database
por: Berthet, Stephanie, et al.
Publicado: (2011)

Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs
por: Colhoun, H. M., et al.
Publicado: (2012)

Influence of health warnings on the use of rosiglitazone and pioglitazone in an area of Spain: A time-series study
por: Carracedo-Martínez, Eduardo, et al.
Publicado: (2016)

Development of Heart Failure in Medicaid Patients with Type 2 Diabetes Treated with Pioglitazone, Rosiglitazone, or Metformin
por: Breunig, Ian M., et al.
Publicado: (2014)

Dual therapy of rosiglitazone/pioglitazone with glimepiride on diabetic nephropathy in experimentally induced type 2 diabetes rats
por: Rao, Ravi Prakash, et al.
Publicado: (2011)

Gamma delta T cells in hepatocellular carcinoma: Sunrise of new therapy based on Vδ2 T cells?
por: Macek Jilkova, Zuzana
Publicado: (2022)

The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety
por: Leonard, Charles E., et al.
Publicado: (2020)

Rosiglitazone and Pioglitazone Utilization from January 2007 Through May 2008 Associated With Five Risk-Warning Events
por: Starner, Catherine I., et al.
Publicado: (2008)

Utilization and Costs for Compliant Patients Initiating Therapy With Pioglitazone or Rosiglitazone Versus Insulin in a Medicaid Fee-for-Service Population
por: Kalsekar, Iftekhar, et al.
Publicado: (2006)

Impairment of adrenergically-regulated thermogenesis in brown fat of obesity-resistant mice is compensated by non-shivering thermogenesis in skeletal muscle
por: Janovska, Petra, et al.
Publicado: (2023)

Reply to Comment on “Jilkova, Z.M.; et al. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges” Cancers 2019, 11, 1554
por: Macek Jilkova, Zuzana, et al.
Publicado: (2020)

Animal Models of Hepatocellular Carcinoma: The Role of Immune System and Tumor Microenvironment
por: Macek Jilkova, Zuzana, et al.
Publicado: (2019)

Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
por: Macek Jilkova, Zuzana, et al.
Publicado: (2019)

Leukemia and rosiglitazone
por: Yavasoglu, Irfan, et al.
Publicado: (2016)

Loss of UCP1 function augments recruitment of futile lipid cycling for thermogenesis in murine brown fat
por: Oeckl, Josef, et al.
Publicado: (2022)

Tissue-specific sex difference in the metabolism of fatty acid esters of hydroxy fatty acids
por: Riecan, Martin, et al.
Publicado: (2023)

Rosiglitazone modulates collagen deposition and metabolism in atherosclerotic plaques of fat-fed ApoE-knockout mice
por: ZHOU, MINGXUE, et al.
Publicado: (2015)

The Chicken Embryo Model: A Novel and Relevant Model for Immune-Based Studies
por: Garcia, Paul, et al.
Publicado: (2021)

The Janus face of rosiglitazone
por: Pich, Christine, et al.
Publicado: (2018)

Immune checkpoints on T and NK cells in the context of HBV infection: Landscape, pathophysiology and therapeutic exploitation
por: Dumolard, Lucile, et al.
Publicado: (2023)

Percutaneous Ablation-Induced Immunomodulation in Hepatocellular Carcinoma
por: Dumolard, Lucile, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i5btm9mv5nka2oei1joninmldv